Bionomics Limited

ABN 53 075 582 740

ASX ANNOUNCEMENT
18 May 2015

BIONOMICS STRENGTHENS LEADERSHIP TEAM

Dr Jens D. Mikkelsen new Chief Scientific Officer
Jack Moschakis appointed Legal Counsel and Company Secretary

Bionomics Limited (ASX:BNO, OTCQX:BNOEF) a leading, global biopharmaceutical company focused on the discovery and development of innovative therapeutics for central nervous system disorders and cancer is pleased to announce the appointment of two senior executives.

Dr Jens D. Mikkelsen, MD PhD – Chief Scientific Officer
Dr Jens Mikkelsen has extensive experience in neuroscience and was one of the founders of Zealand Pharmaceuticals in Glostrup, Denmark. Its first drug was Lixisenatide (marketed as Lyxumia®), a Type 2 diabetes treatment, for which Zealand licensed the global development and commercial rights to Sanofi.

Dr Mikkelsen had leading roles in drug discovery at Lundbeck A/S a global specialty CNS pharmaceutical company, and was the Chief Scientific Officer and Chief Executive Officer for Azign Bioscience A/S prior to its acquisition by NeuroSearch A/S, where then he worked as the Head of the Department of Translational Neurobiology and Scientific Director of CNS Research.

Dr Mikkelsen's work has been published in 285 peer reviewed scientific journals specializing in neuroscience and neuropharmacology. He has over 20 patents for various drugs used for CNS and metabolic disorders.

Dr Mikkelsen holds a Degree in Medicine as well as a Doctorate of Medical Science and is currently professor in translational neuropharmacology at the Neurobiology Research Unit, University Hospital of Copenhagen (UHC) as well as a member of the Danish Council for Independent Research, Medical Sciences.

He has led numerous projects in industrial R&D organizations and currently heads a Strategic Research Project at UHC aimed at identifying novel cognitive enhancers for patients with schizophrenia or Alzheimer's disease.

Jack Moschakis – Legal Counsel and Company Secretary
Mr Moschakis brings a depth of legal knowledge with over 25 years' experience as a legal practitioner. He has worked in senior legal/company secretary roles in the South Australian electricity industry for over 10 years and has expertise in energy law and energy related commercial and contractual matters.

His most recent position was at mining company Rex Minerals Ltd where he worked as a legal consultant. Prior to this, Mr Moschakis worked at Thomsons Lawyers, a top tier Adelaide law firm that is now part of the national law firm of Thomson Geer, as an energy and infrastructure consultant.

Mr Moschakis holds a Bachelor of Economics (Adel), Diploma in Law (NSW) and Graduate Diploma in Business Administration (Adel). He is a Fellow of the Institute of Chartered Secretaries and Member of the Law Society of South Australia.

Dr Deborah Rathjen CEO & Managing Director of Bionomics in welcoming Dr Mikkelsen and Mr Moschakis said “The appointment of Jens as our Chief Scientific Officer and Jack as Legal Counsel & Company Secretary reflect the continuing maturation of Bionomics global operations. Jens is an internationally recognised neuroscientist who brings a wealth of Pharma and Biotech experience which will enhance Bionomics research operations and partnering activities. Jens has a deep understanding of Bionomics from his work on our Scientific Advisory Board and it is a great endorsement to have him join our executive team”.

“With operations in Australia, US and Europe and significant major partnerships I am delighted to welcome Jack in his capacity of Legal Counsel & Company Secretary to the team”.

“This strengthening of the team is anticipated to continue as Bionomics expands its US operations” commented Dr Rathjen.

Both Dr Mikkelsen and Mr Moschakis are based at Bionomics research facility in Adelaide.

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited
Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101 /
0418 160 425
drathjen@bionomics.com.au

Monsoon Communications
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

Stern IR
Beth DelGiacco
+1 212 360 1200
beth@sternir.com

About Bionomics Limited
Bionomics (ASX: BNO) is biopharmaceutical company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, memory loss and pain. Its oncology approach includes cancer stem cell therapeutics.

Bionomics' discovery and development activities are driven by its four proprietary technology platforms: MultiCore®, a diversity orientated chemistry platform for the discovery of small molecule drugs; ionX® , a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system; Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels); and CSC Rx Discovery™, which identifies antibody and small molecule therapeutics that inhibit the growth of cancer stem cells. These platforms drive Bionomics’ pipeline and underpin its established business strategy of securing partners for its key compounds. Bionomics partners include Merck & Co.

www.bionomics.com.au

Factors Affecting Future Performance
This announcement contains "forward-looking" statements within the meaning of the United States’ Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics’ development candidates BNC105, BNC210, BNC101 and BNC420, our acquisitions of Eclipse Therapeutics and Prestwick Chemicals and ability to develop products from their platforms, its licensing deals with Merck & Co, drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors products may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.